Development of activated natural killer (NK) cells mediated immunotherapy in cancer

Completed

• Conditions: Immunotherapy in cancer; Cancer; Malignant neoplasms of independent (primary) multiple sites

• Registration Number: ISRCTN79498301
• Lead Sponsor: Sookmyung Women's University (Korea, South)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-08-08
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Healthy volunteers aged 18 years or older, both males and females
2. Written informed consent

Exclusion Criteria

1. Aged less than 18 years
2. Those who do not speak Korean

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. To find BRMs that lead to the highest levels of NK cell cytotoxicity in the treated blood samples<br>2. To find the optimum dose and duration of treatment with the BRMs found to elicit highest levels of NK cell cytotoxicity

Secondary Outcome Measures

Name	Time	Method
Gene expression profiles associated with peripheral blood lymphocyte (PBL) cytotoxicity and related mechanisms in the blood samples.